JP MORGAN/CALL/ELI LILLY & CO/750/0.01/17.01.25 | Real-time Bid/Ask 04:15:19 2024-06-27 am EDT | ||
| 1.84 EUR / 1.86 EUR | +5.11% |
|
| Current month | +39.68% | ||
| 1 month | +45.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 1.76 | +2.33% |
| 24-06-24 | 1.72 | +0.58% |
| 24-06-21 | 1.71 | -2.29% |
| 24-06-20 | 1.75 | -1.69% |
| 24-06-19 | 1.78 | +2.89% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 04:44 am EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK27UX |
| ISIN | DE000JK27UX8 |
| Date issued | 2024-02-08 |
| Strike | 750 $ |
| Maturity | 2025-01-17 (205 Days) |
| Parity | 100 : 1 |
| Emission price | 0.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.78 € |
|---|---|
| Lowest since issue | 0.78 € |
| Spread | 0.02 € |
| Spread % | 1.07% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
